1c:{"metadata":[["$","title","0",{"children":"NIH VideoCast - Listening to Patients: Lessons Learned in the Development of Cancer Immunotherapy"}],["$","meta","1",{"name":"description","content":"In the past two decades immunotherapy approaches have been shown to be effective for the treatment of selected patients with metastatic cancer. The administration of interleukin-2 or a monoclonal antibody against CTLA-4 can mediate regression of metastatic melanoma in about 15 percent of patients. The administration of in vitro expanded autologous anti-tumor T cells, plus IL-2, following a lymphodepleting chemotherapy results in objective regressions in 50 percent of patients with metastatic melanoma. T cells capable of mediating these regressions have been used to identify dozens of human cancer antigens.\nRecently gene therapy approaches that utilize the transduction of genes encoding anti-tumor T cell receptors has been shown to be effective and hold promise for the application of immunotherapy for the treatment of patients with common epithelial cancers.\n

\nNIH Director's Wednesday Afternoon Lecture Series \n
"}],["$","meta","2",{"name":"publisher","content":"National Institutes of Health"}],["$","meta","3",{"property":"og:title","content":"NIH VideoCast - Listening to Patients: Lessons Learned in the Development of Cancer Immunotherapy"}],["$","meta","4",{"property":"og:description","content":"In the past two decades immunotherapy approaches have been shown to be effective for the treatment of selected patients with metastatic cancer. The administration of interleukin-2 or a monoclonal antibody against CTLA-4 can mediate regression of metastatic melanoma in about 15 percent of patients. The administration of in vitro expanded autologous anti-tumor T cells, plus IL-2, following a lymphodepleting chemotherapy results in objective regressions in 50 percent of patients with metastatic melanoma. T cells capable of mediating these regressions have been used to identify dozens of human cancer antigens.\nRecently gene therapy approaches that utilize the transduction of genes encoding anti-tumor T cell receptors has been shown to be effective and hold promise for the application of immunotherapy for the treatment of patients with common epithelial cancers.\n

\nNIH Director's Wednesday Afternoon Lecture Series \n
"}],["$","meta","5",{"property":"og:url","content":"https://uat.d1rkikwu4q8tg.amplifyapp.com/watch/99bf4d0a-d5db-11f0-9cf9-12c45c580ad9"}],["$","meta","6",{"property":"og:site_name","content":"NIH VideoCast"}],["$","meta","7",{"property":"og:image","content":"https://nihcit.rev.vbrick.com/api/v2/media/videos/thumbnails/514cb32f-1088-409d-80bb-e72e9f78354d.jpg"}],["$","meta","8",{"property":"og:type","content":"website"}],["$","meta","9",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","10",{"name":"twitter:title","content":"NIH VideoCast - Listening to Patients: Lessons Learned in the Development of Cancer Immunotherapy"}],["$","meta","11",{"name":"twitter:description","content":"In the past two decades immunotherapy approaches have been shown to be effective for the treatment of selected patients with metastatic cancer. The administration of interleukin-2 or a monoclonal antibody against CTLA-4 can mediate regression of metastatic melanoma in about 15 percent of patients. The administration of in vitro expanded autologous anti-tumor T cells, plus IL-2, following a lymphodepleting chemotherapy results in objective regressions in 50 percent of patients with metastatic melanoma. T cells capable of mediating these regressions have been used to identify dozens of human cancer antigens.\nRecently gene therapy approaches that utilize the transduction of genes encoding anti-tumor T cell receptors has been shown to be effective and hold promise for the application of immunotherapy for the treatment of patients with common epithelial cancers.\n

\nNIH Director's Wednesday Afternoon Lecture Series \n
"}],"$L22","$L23","$L24"],"error":null,"digest":"$undefined"}